Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis to speed access to $10 billion heart drug via NHS deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2020 | 01:14pm EST
FILE PHOTO: Logo is seen at new factory of Novartis in Stein

Novartis and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021.

Novartis hopes the NHS deal will boost sales of cholesterol-lowering inclisiran, which the Swiss drugmaker bought in a deal announced last year for nearly $10 billion (£7.70 billion) and predicts will be a top seller.

Inclisiran was submitted to U.S. regulators last year, and Novartis expects a European submission in coming weeks.

The pact also calls for a UK clinical trial, based on proprietary NHS data, to identify patients at risk of heart disease for whom conventional treatment has not worked, as well as a collaboration on manufacture of cutting-edge drugs like inclisiran, which targets "bad cholesterol", a culprit behind heart attacks and strokes.

Heart disease or hardening of the arteries is a big killer in Britain and the NHS has made fighting cardiovascular disorders one of its long-term priorities.

"If licensed, it will allow the drug to be put through the NICE approval process at the earliest opportunity possible, making it available to NHS patients much earlier," Britain's Department of Health and Social Care (DHSC) said, in response to Reuters questions.

Should inclisiran win U.K. approval, as expected, the deal calls for the NHS to pay for it as an add-on therapy for those patients whose cholesterol levels do not respond adequately to statins, at a significantly reduced price.

The DHSC did not release the agreed price, citing commercial confidentiality. It also declined to comment on whether Novartis would be required to make inclisiran in Britain.

British health minister Matt Hancock said: "This collaboration has the potential to save 30,000 lives over the next ten years."

RIVAL DRUGS

Novartis bought inclisiran with its $9.7 billion acquisition of The Medicines Co., announced in late November, to expand a cardiovascular medicines portfolio that already includes heart failure drug Entresto, a billion-dollar-per-year seller.

Novartis Chief Executive Vas Narasimhan has predicted inclisiran will become one of Novartis's most-lucrative medicines but has warned of "a few years of slow ramp" before sales take off.

Narasimhan has said inclisiran's price tag would be in the "cost-effective range" to compete with rival medicines, Amgen Repatha and Praluent from Regeneron and Sanofi.

They list at some $5,800 annually in th
e United States, following price cuts undertaken to boost slumping sales. [https://reut.rs/2NiOj72] [https://reut.rs/2FKb0Nt]

Inclisiran is a twice-yearly injection, while Repatha and Praluent are injected every two weeks.

(Reporting by John Miller. Editing by Jane Merriman)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN -0.36% 236.75 Delayed Quote.-1.44%
NOVARTIS 0.69% 92.72 Delayed Quote.0.27%
REGENERON PHARMACEUTICALS -1.26% 359.14 Delayed Quote.-3.13%
SANOFI 0.79% 89.57 Real-time Quote.-0.84%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
01/16AMGEN : Patricia Turney Joins Arcutis as Senior Vice President, Manufacturing
AQ
01/14AMGEN : 38th Annual J.P. Morgan Healthcare Conference Presentation
PU
01/14Amgen CEO expects 25% of growth to come from Asia in next decade
RE
01/13AMGEN : Announces Global Diagnostic Collaborations To Expand Molecular Testing F..
PR
01/13Novartis to speed access to $10 billion heart drug via NHS deal
RE
01/13Drugmakers Test New Ways to Pay for Six-Figure Treatments
DJ
01/13Bristol-Myers Deal Starts to Pay Off as Treatments Advance -- WSJ
DJ
01/12BRISTOL'S MERGER WITH CELGENE IS ALR : Ceo
DJ
01/09AMGEN : To Present At The 38th Annual J.P. Morgan Healthcare Conference
PR
01/07AMGEN : To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted C..
PR
More news
Financials (USD)
Sales 2019 23 191 M
EBIT 2019 11 131 M
Net income 2019 7 881 M
Debt 2019 19 048 M
Yield 2019 2,45%
P/E ratio 2019 18,4x
P/E ratio 2020 16,8x
EV / Sales2019 6,89x
EV / Sales2020 6,43x
Capitalization 141 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 241,83  $
Last Close Price 236,75  $
Spread / Highest target 20,4%
Spread / Average Target 2,15%
Spread / Lowest Target -26,9%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN-1.44%140 673
JOHNSON & JOHNSON2.33%390 175
ROCHE HOLDING AG5.10%290 856
MERCK AND COMPANY-1.08%228 247
PFIZER2.58%222 416
NOVARTIS1.08%215 253